Chemo combination promising for multiple myeloma

Chemo combination promising for multiple myeloma
For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in the Journal of Clinical Oncology.

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in the Journal of Clinical Oncology.

Sagar Lonial, M.D., of the Winship Cancer Institute at Emory University in Atlanta, and colleagues conducted a phase I study to evaluate the dose-limiting toxicities and response rates associated with elotuzumab, , and low-dose dexamethasone treatment in 28 patients with relapsed or refractory multiple myeloma (median, three prior therapies). Patients were treated with 5, 10, or 20 mg/kg elotuzumab, plus lenalidomide and dexamethasone.

The researchers found no dose-limiting toxicities up to the maximum 20-mg/kg dose of elotuzumab. Neutropenia (36 percent) and thrombocytopenia (21 percent) were the most frequently reported grade 3 or 4 toxicities. Two serious infusion reactions, including one grade 4 anaphylactic reaction and one grade 3 stridor, occurred in two patients during the first treatment cycle. A total of 82 percent of patients exhibited objective responses. For patients treated until disease progression, after a median of 16.4 months follow-up, the median time to progression was not reached for patients in the 20-mg/kg cohort.

"The combination of elotuzumab, lenalidomide, and dexamethasone appears to be active, with results from this phase I study suggesting enhanced efficacy over lenalidomide and low-dose alone," the authors write. "Further validation of the dose, safety, and efficacy in larger patient populations is warranted and underway."

More information: doi: 10.1200/JCO.2011.37.2649

Related Stories

Multiple myeloma clinical trial closes early

date Apr 05, 2007

Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose ...

Recommended for you

Cancer diagnoses will rise as population ages

date 2 hours ago

Cancer is a leading cause of death in Virginia and researchers at the University of Virginia's Weldon Cooper Center for Public Service project that the rate of growth in new cancer cases will far outpace ...

Omega-3 hope for cancer patients

date 3 hours ago

The chemistry involved in designing drugs with the potential to treat cancer is complex and finicky. The placement of a single atom can be the difference between a cancer killer and a useless bystander. And ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.